NCT04413266

Effects of Curcumin Supplementation in Patients With Chronic Kidney Disease on Peritoneal Dialysis

Completed NA Last updated 14 December 2023

What this trial tests

NA trial testing Curcumin supplementation in Chronic Kidney Diseases in 30 participants. Completed in 5 October 2023.

Timeline

10 October 2020

Primary endpoint
5 October 2023

5 October 2023

Quick facts

Lead sponsor	Universidade Federal Fluminense
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	health services research
Enrollment	30
Start date	10 October 2020
Primary completion	5 October 2023
Estimated completion	5 October 2023
Sites	1 location across Brazil

Drugs / interventions tested

• Curcumin supplementation

Conditions studied

• Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
• Peritoneal Dialysis — all drugs for Peritoneal Dialysis →
• Hemodialysis — all drugs for Hemodialysis →

Sponsor

Universidade Federal Fluminense — full company profile →

Who can join

Adults 18 to 60, any sex, with Chronic Kidney Diseases or Peritoneal Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to assess whether supplementation with curcumin could modulate the intestinal microbiota, reducing levels of inflammatory markers of oxidative stress, uremic toxins and inflammasome, in patients with chronic kidney disease in peritoneal dialysis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.
   Forman HJ, Zhang H. · · 2021 · cited 1789× · PMID 34194012 · DOI 10.1038/s41573-021-00233-1
2. Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling.
   Uddin MJ, Kim EH, Hannan MA, Ha H. · · 2021 · cited 75× · PMID 33562389 · DOI 10.3390/antiox10020258
3. The Regulatory Effect of Phytochemicals on Chronic Diseases by Targeting Nrf2-ARE Signaling Pathway.
   He WJ, Lv CH, Chen Z, Shi M, et al · · 2023 · cited 46× · PMID 36829795 · DOI 10.3390/antiox12020236
4. Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases.
   Grunenwald A, Roumenina LT, Frimat M. · · 2021 · cited 35× · PMID 33670516 · DOI 10.3390/ijms22042009
5. Can curcumin supplementation break the vicious cycle of inflammation, oxidative stress, and uremia in patients undergoing peritoneal dialysis?
   Reis DCMV, Alvarenga L, Cardozo LFMF, Baptista BG, et al · · 2024 · cited 19× · PMID 38220413 · DOI 10.1016/j.clnesp.2023.11.015
6. The Mitochondrion: A Promising Target for Kidney Disease.
   Tanriover C, Copur S, Ucku D, Cakir AB, et al · · 2023 · cited 19× · PMID 36839892 · DOI 10.3390/pharmaceutics15020570
7. Putative role of natural products as Protein Kinase C modulator in different disease conditions.
   Singh RK, Kumar S, Tomar MS, Verma PK, et al · · 2021 · cited 11× · PMID 34216003 · DOI 10.1007/s40199-021-00401-z
8. Connecting epigenetics and inflammation in vascular senescence: state of the art, biomarkers and senotherapeutics.
   Fraile-Martinez O, De Leon-Oliva D, Boaru DL, De Castro-Martinez P, et al · · 2024 · cited 8× · PMID 38469117 · DOI 10.3389/fgene.2024.1345459